Physician profile
Mark W Graves
NPI 1285702308
$998.62
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $63.52.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $310.00 | 2019 | |
| Amarin Pharma, INC. | $155.34 | 2019-2020 | |
| Novo Nordisk INC | $132.64 | 2019-2020 | |
| Amgen INC. | $92.21 | 2019 | |
| Allergan, INC. | $64.07 | 2019-2020 | |
| Glaxosmithkline, LLC. | $47.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.21 | 2019 | |
| Merck Sharp & Dohme LLC | $26.66 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.16 | 2019 | |
| Shire North American Group INC | $25.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.96 | 2019 | |
| Sanofi Pasteur INC. | $18.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.91 | 2019 | |
| Lilly USA, LLC | $11.74 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.34 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $10.82 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.